Chris Pericak and Caitlin Visek, Technology Insights
Investment in positron emission tomography (PET) technology used to be a safe bet for a growing oncology program. However, the Centers for Medicaid and Medicare Services (CMS) is expected to deliver a ruling in the coming weeks that could limit PET coverage to one scan for most cancer indications.
In light of potential coverage limitations, hospitals will have to employ greater caution when assessing the profitability of future PET purchases.
How will CMS’s PET scan ruling impact your investment strategy?
Alyssa Pollizzi and Rachel Klein
In February 2011, the FDA approved tomosynthesis as a breast cancer screening and diagnostic tool. Unlike traditional 2D mammography, DBT captures multiple images from the breast and reconstructs them to form a 3D image.
Fast forward to 2013. Clinical evidence has yet to convince the radiology community that the higher cost of the tomo system, longer radiologist read time, and additional radiation dosage is worth it. Practitioners also wonder which population this technology is best suited for - Screening? Diagnostic? Dense breasted women? A firm answer isn't available.
Tomo on the rise: DBT shows improvement in screening setting
Christopher Pericak and Jason Doran
When it comes to lung CT screening, it might be time to start choosing sides. This month, the American Cancer Society acted in favor of screening by releasing new guidelines concerning the use of CT screening for patients with a high risk of developing lung cancer. But will these new guidelines translate to increased adoption of this technology?
Will new American Cancer Society guidelines spur adoption of lung CT screening?